1. Pink Sheet
  2. >>Drug Safety

Ireland Chooses "Blueprint" System To Link Into Future EU Product Verification Network

 
• By Ian Schofield

New Irish system will link into the European verification network that is being set up to detect incidents of falsified medicines entering the supply chain using a "unique identifier" on most packs of prescription drugs, starting from February 2019.

Industry, pharmacist and wholesaler associations in Ireland are setting up a new not-for-profit body, the Irish Medicines Verification Organisation (IMVO), to implement and manage a national repository of "unique identifiers" that will have to be placed on the majority of prescription medicines from February 2019.

The Irish repository is one of a number of similar systems being set up around Europe that will...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Safety

Hong Kong To End Reliance On Overseas Drug Approvals

 
• By Anabel Costa-Ferreira

Hong Kong is pushing forward with its vision to build an “internationally renowned” regulatory authority of drugs and medical devices. Meanwhile, the Department of Health’s 1+ drug registration mechanism has received over 620 enquiries from over 160 pharmaceutical companies.

Inexperience And Confusion: ACIP Struggles To End MMRV, Hep B Debates

 
• By Bridget Silverman

Confusion, inconsistency and strongly held views complicated the CDC's Advisory Committee on Immunization Practices' votes to change vaccine recommendations for the measles, mumps, rubella, varicella vaccine in young children and tabling of a vote on hepatitis B vaccine at birth.

More Vaccines At Risk At Upcoming ACIP Meeting As New Panel Members Join

 
• By Sarah Karlin-Smith

The ACIP put hepatitis B and MMRV vaccines on its agenda, despite having no new reason to relitigate the products, worrying public health experts that more anti-vaccine moves are coming.

Intercept Withdraws Ocaliva From US, The PBC Drug’s Last Market

 
• By Mandy Jackson

Intercept will voluntarily take Ocaliva off the market at the request of the US FDA, which put the clinical trials of the primary biliary cholangitis drug on a clinical hold.

More from Pink Sheet

ACIP Weakened COVID-19 Vaccine Advice, But Less Than Rhetoric May Suggest

 
• By Sarah Karlin-Smith

The new recommendations should not change insurance coverage, but the tone of the meeting frustrated many medical experts, because of the negative comments on the vaccines.

Inexperience And Confusion: ACIP Struggles To End MMRV, Hep B Debates

 
• By Bridget Silverman

Confusion, inconsistency and strongly held views complicated the CDC's Advisory Committee on Immunization Practices' votes to change vaccine recommendations for the measles, mumps, rubella, varicella vaccine in young children and tabling of a vote on hepatitis B vaccine at birth.

US FDA Appears To Be Managing MAHA Well By Feeding Instead Of Receiving Priorities

 
• By Ramsey Baghdadi

The newly issued Make America Healthy Again strategy report suggests that FDA leaders are doing a good job of feeding ideas to the Trump Administration, rather than having the agency agenda dictated from above.